Alcohol Use Disorder

Alcohol Use Disorder (AUD) is a chronic, relapsing condition defined by compulsive alcohol use, loss of control over intake, and a negative emotional state during withdrawal. DSM-5-TR classifies it under Substance-Related and Addictive Disorders. It merged the older DSM-IV categories of "alcohol abuse" and "alcohol dependence" into a single dimensional diagnosis with severity grading. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Alcohol Use Disorder (AUD) is a chronic, relapsing condition defined by compulsive alcohol use, loss of control over intake, and a negative emotional state during withdrawal. DSM-5-TR classifies it under Substance-Related and Addictive Disorders. It merged the older DSM-IV categories of "alcohol abuse" and "alcohol dependence" into a single dimensional diagnosis with severity grading. AUD affects approximately 29.5 million Americans aged 12 and older (2022 NSDUH data), yet only ~7.6% of affected individuals receive any treatment. Alcohol is the third leading preventable cause of death in the United States, responsible for ~140,000 deaths annually (CDC). The condition produces damage across virtually every organ system, drives enormous healthcare costs (~$249 billion annually in the USA), and carries high comorbidity with depression, anxiety, PTSD, and other substance use disorders. This information is for psychoeducation only.

DSM-5-TR identifies 11 diagnostic criteria. Any 2 or more within a 12-month period confirm the diagnosis. The criteria are: (1) drinking more or longer than intended; (2) persistent desire or unsuccessful efforts to cut down; (3) spending a great deal of time obtaining, using, or recovering from alcohol; (4) craving - a strong urge to drink; (5) recurrent use resulting in failure to fulfil major role obligations (work, school, home); (6) continued use despite persistent social or interpersonal problems caused by alcohol; (7) important social, occupational, or recreational activities given up or reduced; (8) recurrent use in physically hazardous situations; (9) continued use despite knowledge of a physical or psychological problem caused or worsened by alcohol; (10) tolerance - needing increased amounts or diminished effect with continued use; (11) withdrawal - characteristic withdrawal syndrome or drinking to relieve/avoid withdrawal. Severity: mild = 2-3 criteria; moderate = 4-5; severe = 6+. Physical signs: facial flushing, spider angiomata, palmar erythema, hepatomegaly, tremor, poor nutrition, parotid gland enlargement, Dupuytren contracture, testicular atrophy, gynecomastia.

Genetic: heritability ~50%; family history of AUD increases risk 3-4 fold. Specific gene variants affecting alcohol metabolism (ADH1B, ALDH2) modify risk - the ALDH2*2 allele (common in East Asian populations) produces acetaldehyde accumulation after drinking, creating an aversive flushing response that is protective. GABRA2, CHRM2, and OPRM1 gene variants contribute modest risk.

Psychiatric: comorbid depression, bipolar disorder, PTSD, ADHD, conduct disorder, and antisocial personality disorder each increase AUD risk 2-4 fold. Anxiety disorders often precede AUD as individuals use alcohol to self-medicate. Environmental: early age of first drink (before age 15 doubles lifetime AUD risk); peer drinking; childhood adversity and trauma (ACE scores >=4 increase AUD risk ~7 fold); low socioeconomic status; easy alcohol availability; cultural norms normalising heavy drinking. Sex: men have higher prevalence, but the gender gap has narrowed over recent decades. Women develop alcohol-related liver disease and cardiomyopathy at lower cumulative doses ("telescoping").

AUD results from interaction between genetic vulnerability, neurobiological adaptation, and environmental exposure. Alcohol increases dopamine release in the ventral tegmental area (VTA) projecting to the nucleus accumbens, producing reinforcing euphoria. It enhances GABA-A receptor activity (inhibitory, sedating, anxiolytic) and inhibits NMDA glutamate receptors (excitatory). Repeated heavy use triggers neuroadaptation: GABA-A receptors downregulate (tolerance to sedation) and NMDA receptors upregulate (excitatory rebound during withdrawal). The endogenous opioid system contributes: alcohol triggers beta-endorphin and enkephalin release, reinforcing drinking. Naltrexone blocks this pathway. Serotonin (5-HT) dysfunction - particularly reduced 5-HT transmission in the raphe nuclei - is associated with impulsive, early-onset AUD (Cloninger Type II). Chronic use engages the brain's stress systems: the extended amygdala releases corticotropin-releasing factor (CRF) and norepinephrine during withdrawal, producing dysphoria and anxiety that drive further drinking (negative reinforcement). This shift from positive to negative reinforcement marks the transition from controlled use to addiction. Epigenetic changes (histone acetylation, DNA methylation) in prefrontal and striatal regions contribute to long-term vulnerability and relapse even after prolonged abstinence.

In the USA, ~29.5 million people aged 12+ met criteria for AUD in 2022 (NSDUH). Lifetime prevalence of AUD is approximately 29% in the general population (NESARC data). Globally, alcohol use causes ~3 million deaths per year (WHO, 5.3% of all deaths). The 12-month prevalence of AUD in US adults is ~11%. Sex: men have roughly 2:1 prevalence over women, though the gap is narrowing. Age: AUD peaks in 18-29 year-olds. Native American and Alaska Native populations have the highest AUD prevalence in the USA (~15%); Asian Americans have the lowest (~5%). Socioeconomic status shows a complex relationship: higher income groups drink more frequently, but lower income groups experience more alcohol-related harm per unit consumed. Comorbidity: ~40% of individuals with AUD have a co-occurring mood disorder; ~20% have an anxiety disorder; ~15% have another substance use disorder. AUD accounts for ~7.4% of US emergency department visits and over 200,000 hospitalisations annually.

Acute intoxication: alcohol potentiates GABA-A inhibitory transmission and blocks NMDA glutamate receptors, producing sedation, anxiolysis, and impaired coordination. At blood alcohol concentrations (BAC) >0.30%, respiratory depression and death can occur. Chronic use produces neuroadaptation: GABA-A receptor subunit composition changes reduce sensitivity (tolerance); NMDA receptor upregulation creates a hyperexcitable state unmasked during withdrawal. This excitatory-inhibitory imbalance explains withdrawal seizures and delirium tremens. Kindling: repeated withdrawal episodes progressively lower the seizure threshold through glutamate-mediated excitotoxicity, making each successive withdrawal more dangerous than the last. Organ damage: hepatic steatosis progresses to alcoholic hepatitis to cirrhosis (~10-20% of heavy drinkers develop cirrhosis). Chronic alcohol use produces dilated cardiomyopathy, pancreatitis (acute and chronic), bone marrow suppression (macrocytic anaemia, thrombocytopenia), peripheral neuropathy (thiamine-dependent), and cerebellar degeneration. Wernicke encephalopathy (confusion, ataxia, ophthalmoplegia from thiamine deficiency) can progress to Korsakoff syndrome (irreversible anterograde and retrograde amnesia) if untreated. Alcohol increases risk of oropharyngeal, oesophageal, liver, colorectal, and breast cancers. The risk rises with dose - there is no safe threshold for cancer risk.

Screening: the CAGE questionnaire (Cut down, Annoyed, Guilty, Eye-opener; >=2 positive = sensitivity ~85% for AUD) is brief but lacks sensitivity for hazardous drinking. The AUDIT (Alcohol Use Disorders Identification Test; 10 items, score >=8 = hazardous use) is the gold-standard screening instrument and detects the full spectrum from risky drinking to severe AUD. The AUDIT-C (first 3 questions) is an efficient alternative. The Single Alcohol Screening Question ("How many times in the past year have you had 5 or more drinks in a day?" >=1 = positive) has good sensitivity. History: quantity/frequency of drinking, pattern (daily vs. binge), age of onset, withdrawal history (seizures, DTs), prior treatment attempts, and consequences (legal, occupational, relational, medical). Assess for concomitant substance use, psychiatric symptoms, and suicidality.

Physical exam: alcohol on breath, tremor, diaphoresis, tachycardia, hypertension, hepatomegaly, jaundice, spider angiomata, palmar erythema, ascites, gynecomastia, testicular atrophy, peripheral neuropathy (stocking-glove sensory loss), cerebellar signs (ataxia, dysmetria), Dupuytren contracture.

DSM-5-TR diagnosis: a problematic pattern of alcohol use leading to clinically significant impairment or distress, manifested by >=2 of the 11 criteria within a 12-month period. Severity specifiers: mild (2-3 criteria), moderate (4-5), severe (6+). Specifiers: in early remission (3-12 months without criteria except craving), in sustained remission (>12 months), in a controlled environment. ICD-11 code: 6C40 (Alcohol dependence) and 6C40.0-6C40.2 for current use, early remission, sustained remission. ICD-11 also includes 6C40.Z for hazardous alcohol use as a separate category (QE11.0). Key distinction from DSM-IV: DSM-5 eliminated the abuse/dependence split. The addition of "craving" as a criterion and removal of "legal problems" were significant changes. The dimensional severity model replaced the categorical approach.

Laboratory markers of heavy alcohol use: gamma-glutamyl transferase (GGT) - elevated in ~70% of heavy drinkers, but non-specific; mean corpuscular volume (MCV) - macrocytosis from folate/B12 deficiency and direct marrow toxicity; carbohydrate-deficient transferrin (CDT) - most specific single marker (~90% specificity), reflects heavy drinking over 2-3 weeks; phosphatidylethanol (PEth) - detects use over 3-4 weeks with high sensitivity and specificity; ethyl glucuronide (EtG) in urine - detects alcohol exposure over 3-5 days. Liver function: AST:ALT ratio >2:1 suggests alcoholic liver disease (vs. other causes where ALT typically exceeds AST). Elevated bilirubin, low albumin, and prolonged INR indicate advancing liver disease. Hepatic ultrasound or FibroScan evaluates for steatosis, fibrosis, or cirrhosis. Comprehensive metabolic panel: hypomagnesaemia, hypokalaemia, hypophosphataemia common in heavy drinkers. CBC: macrocytic anaemia, thrombocytopenia. Thiamine and folate levels. Hepatitis B and C serologies (shared risk factors). Lipase if pancreatitis suspected. Withdrawal assessment: the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is a 10-item scale scoring withdrawal severity (0-67). Scores >=10 indicate clinically significant withdrawal requiring pharmacological treatment.

Other substance use disorders: benzodiazepine or barbiturate use can produce similar intoxication and withdrawal syndromes; urine drug screen and history differentiate. Hepatic encephalopathy: confusion and asterixis in a patient with known liver disease may be mistaken for intoxication. Hypoglycaemia: altered mental status, diaphoresis, and tremor mimic intoxication; fingerstick glucose clarifies. Wernicke encephalopathy: the triad (confusion, ataxia, ophthalmoplegia) can occur in any malnourished patient, not just drinkers; always give thiamine before glucose. Mood disorders: major depression and bipolar disorder commonly co-occur with AUD; substance-induced mood disorder must be distinguished from independent mood disorders by observing symptoms during >=4 weeks of abstinence.

Anxiety disorders: generalised anxiety and panic disorder overlap significantly with alcohol withdrawal symptoms; differentiation requires extended observation during sobriety. Antisocial personality disorder: behavioural features overlap with conduct-subtype alcohol-related problems.

Treatment of Alcohol Use Disorder (AUD) involves a phased approach: acute management (detoxification if needed), rehabilitation, and long-term recovery support. Acute Management and Detoxification: Medically supervised withdrawal management is essential for patients with significant physical dependence due to the risk of withdrawal seizures and delirium tremens. Benzodiazepines (chlordiazepoxide, diazepam, lorazepam) are the standard of care for alcohol withdrawal, using either fixed-dose or symptom-triggered protocols guided by the CIWA-Ar scale. Thiamine supplementation (500mg IV three times daily for 3-5 days, then 100mg oral daily) is given to prevent Wernicke encephalopathy. Delirium tremens occurs in ~3-5% of hospitalised withdrawal patients, typically 48-72 hours after last drink, with mortality of ~1-4% when treated (historically 15-20% untreated). Pharmacotherapy for Relapse Prevention: Naltrexone (oral 50mg daily or long-acting injectable 380mg monthly) reduces heavy drinking days and craving by blocking mu-opioid receptors involved in the rewarding effects of alcohol. Number needed to treat (NNT) to prevent return to any drinking is ~12; NNT to prevent return to heavy drinking is ~8. Contraindicated in patients on opioid agonists or with acute hepatitis. Acamprosate (666mg three times daily) stabilises glutamatergic neurotransmission disrupted by chronic alcohol use and reduces relapse rates in abstinent patients. Eliminated renally; cannot be used in severe renal impairment. Disulfiram (250mg daily) produces an aversive reaction (flushing, nausea, vomiting, tachycardia, hypotension) when alcohol is consumed through inhibition of aldehyde dehydrogenase, causing acetaldehyde accumulation. Benefits highly motivated patients with good social support for supervised administration. Topiramate (up to 300mg daily) and gabapentin (up to 1800mg daily) have emerging evidence for reducing heavy drinking days; both are off-label. Psychotherapy: Motivational Enhancement Therapy (MET) addresses ambivalence about change and strengthens intrinsic motivation. Cognitive-behavioural therapy (CBT) teaches coping skills for high-risk situations, craving management, and relapse prevention. Twelve-step facilitation helps patients engage with mutual-help organisations. Contingency management uses positive reinforcement for abstinence. Brief interventions are effective in primary care settings for hazardous drinking. Psychosocial Support: Alcoholics Anonymous and other mutual-help groups provide ongoing peer support. Family therapy (Community Reinforcement and Family Training - CRAFT) helps family members support recovery. Vocational rehabilitation, housing support, and treatment of comorbid conditions (depression, anxiety, PTSD) are important components of care.

AUD follows variable trajectories. About one-third of individuals with AUD achieve full remission within 3 years of diagnosis even without treatment ("natural recovery"), typically those with mild severity and strong social support. With treatment, approximately 50-60% achieve at least 1 year of abstinence or controlled drinking. Naltrexone reduces heavy drinking by ~36% compared to placebo.

The COMBINE study showed that naltrexone combined with medical management produced outcomes comparable to specialised behavioural therapy. Relapse rates are high: ~40-60% relapse within the first year after treatment. Each successive withdrawal episode worsens prognosis due to kindling. Mortality is elevated: individuals with severe AUD have 3-4 times the age-adjusted mortality rate. Liver disease, cardiovascular events, cancer, accidents, and suicide are the leading causes of death. Sustained abstinence of 5+ years reduces mortality risk toward baseline but does not fully eliminate it (especially for cancer risk). Protective factors: stable employment, intact marriage, engagement with mutual-help groups, absence of comorbid drug use, and completion of a treatment programme.

Hepatic: fatty liver (steatosis, reversible) -> alcoholic hepatitis (10-35% mortality for severe cases) -> cirrhosis (develops in 10-20% of chronic heavy drinkers; 5-year survival ~50% if drinking continues). Hepatocellular carcinoma risk increases with cirrhosis. Neurological: Wernicke encephalopathy (acute, reversible with thiamine) -> Korsakoff syndrome (chronic, ~20% recovery); peripheral neuropathy in ~25-66% of chronic drinkers; cerebellar degeneration; alcohol-related dementia. Cardiovascular: dilated cardiomyopathy; atrial fibrillation ("holiday heart"); hypertension. Gastrointestinal: pancreatitis (acute and chronic); gastritis; oesophageal varices (from portal hypertension). Haematological: macrocytic anaemia, thrombocytopenia, leukopenia. Psychiatric: depression (present in ~40% of AUD patients), anxiety, psychotic symptoms during withdrawal, increased suicide risk (AUD increases suicide risk ~10 fold). Foetal alcohol spectrum disorders from prenatal exposure - the leading preventable cause of intellectual disability. Cancer: established dose-dependent risk increase for breast, oropharynx, oesophagus, liver, colorectal cancers.

Population-level prevention: raising alcohol taxes reduces consumption and alcohol-related deaths - a 10% price increase reduces consumption by ~7%. Restricting alcohol advertising, limiting outlet density and hours of sale, and raising the minimum legal drinking age are evidence-based policy interventions. Screening and brief intervention (SBI) in primary care is effective: 10-15 minutes of structured feedback about drinking patterns reduces hazardous drinking by ~20-25%. The USPSTF gives SBI a grade B recommendation. Patient education: AUD is a medical condition with neurobiological underpinnings - not a moral failing. Effective treatments exist. Withdrawal can be medically dangerous - never attempt unsupervised detoxification after heavy or prolonged use. Craving is a normal part of recovery and diminishes with time and treatment. Relapse does not mean failure; it indicates the need for treatment adjustment. Alcohol interacts dangerously with many medications (benzodiazepines, opioids, warfarin, metformin). No amount of alcohol is considered safe during pregnancy.

1784: Benjamin Rush published "An Inquiry into the Effects of Ardent Spirits," one of the first medical descriptions of alcohol addiction. 1849: Magnus Huss coined "alcoholism" as a medical term. 1935: Alcoholics Anonymous (AA) founded by Bill Wilson and Bob Smith in Akron, Ohio. 1956: the American Medical Association declared alcoholism a disease. 1960: E.M. Jellinek published "The Disease Concept of Alcoholism," describing progressive stages (alpha through epsilon types). 1980: DSM-III introduced separate diagnoses of "alcohol abuse" and "alcohol dependence." 1992: naltrexone approved by FDA for AUD treatment. 1994: DSM-IV refined abuse and dependence criteria; "physiological dependence" specifier added. 2004: acamprosate approved by FDA. 2006: Vivitrol (injectable naltrexone) approved. 2013: DSM-5 merged abuse and dependence into the single AUD diagnosis with dimensional severity, added craving as a criterion, dropped legal problems.

Alcohol is the most widely used psychoactive substance globally, deeply embedded in social rituals, religious ceremonies, and cultural identity. This normalisation makes AUD uniquely difficult to address. "Drink culture" in many Western societies glorifies heavy consumption while stigmatising those who develop dependence. Stigma: individuals with AUD face significant discrimination in healthcare, employment, and insurance. The framing of alcoholism as a "choice" rather than a medical condition persists in public perception. Terms like "alcoholic" and "drunk" carry pejorative weight; clinicians increasingly use "person with alcohol use disorder." Disparities: Native American communities experience disproportionately high rates of AUD and alcohol-related mortality, linked to historical trauma and systemic marginalisation. Black Americans have lower drinking rates overall but experience higher rates of alcohol-related morbidity and mortality per unit consumed. The alcohol industry disproportionately targets low-income communities and communities of colour with advertising. Economic impact: AUD costs the US economy ~$249 billion annually (2010 estimate, CDC) from healthcare, lost productivity, law enforcement, and criminal justice costs. Approximately 10,000 people die annually in alcohol-impaired driving crashes in the USA.

Pharmacogenomics: OPRM1 A118G polymorphism predicts enhanced naltrexone response in some studies; CYP2E1 variants influence alcohol metabolism and hepatotoxicity risk. The MATCH and COMBINE trials established the evidence base for matching patients to treatments. Novel medications under investigation: nalmefene (mu-opioid partial agonist/kappa antagonist, approved in EU for AUD); sodium oxybate (for maintaining abstinence in Europe); GLP-1 receptor agonists (semaglutide) showing reduced alcohol consumption in preclinical and early clinical data; psilocybin-assisted therapy in combination with motivational enhancement has shown high abstinence rates in two small RCTs. Neuroimaging: resting-state fMRI studies identify disrupted connectivity between prefrontal cortex and striatum as a biomarker of relapse vulnerability. The Addictions Neuroclinical Assessment (ANA) framework classifies AUD into three neurofunctional domains: incentive salience, negative emotionality, and executive function, aiming to guide personalised treatment.

Digital interventions: smartphone-based ecological momentary interventions (EMI) deliver real-time support during craving episodes. Telehealth prescribing of naltrexone has expanded access during and after the COVID-19 pandemic.

APA. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls [Internet]. Alcohol Use Disorder. NCBI Bookshelf. StatPearls Publishing. WHO. (2022). ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization. NIAAA. Alcohol Use Disorder (AUD) in the United States. https://www.niaaa.nih.gov

StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK436003/ NIAAA: https://www.niaaa.nih.gov NIMH: https://www.nimh.nih.gov SAMHSA National Helpline: https://www.samhsa.gov/find-help/national-helpline (1-800-662-4357) WHO ICD-11 code 6C40: https://icd.who.int Rethinking Drinking (NIAAA): https://www.rethinkingdrinking.niaaa.nih.gov Crisis: 988 (US Suicide & Crisis Lifeline); Text HOME to 741741 (Crisis Text Line) Note: Educational only. Not a substitute for professional care.